Castuner

In the Interim...

Berry

A podcast on statistical science and clinical trials.Explore the intricacies of Bayesian statistics and adaptive clinical trials. Uncover methods that push beyond conventional paradigms, ushering in data-driven insights that enhance trial outcomes while ensuring safety and efficacy. Join us as we dive into complex medical challenges and regulatory landscapes, offering innovative solutions tailored for pharma pioneers. Featuring expertise from industry leaders, each episode is crafted to provide clarity, foster debate, and challenge mainstream perspectives, ensuring you remain at the forefront of clinical trial excellence.

Web del podcast

Escolta'l a la teva aplicació

Episodis

84 episodis

  1. Mailbag: Learning Healthcare, Multiplicities, and the Pace of Innovation 47:06
  2. Reflecting on EMA Reflections on Platform Trials 44:18
  3. Statistical Methodology Groups in the Pharmaceutical Industry 55:35
  4. A Discussion on Virtual Controls 47:28
  5. Clinical Trial Arenas: Direct Communication to Patients 43:02
  6. Science Coaching With Alun Bedding 45:11
  7. The CHIPS Trial: Bayesian Adaptive Trial in JAMA 45:40
  8. NFL Study of CTE: The Issues 38:46
  9. Talkin' 'bout Sweet Time 47:03
  10. Mammograms: Death Threats, Hillary Clinton and Lead-Time Bias 1:05:42
  11. REMAP-CAP Results: Oseltamivir in Critically-Ill Influenza Patients 51:58
  12. ICECAP: The Results 54:42
  13. Failure of the Proportional Odds is the Result 40:20
  14. Adaptive Design Actions Matrix 30:43
  15. A Visit With Tim Berry 44:20
  16. Fairness in Soccer and Clinical Trials 34:33
  17. Bias in Stopping Trials Early 39:29
  18. A Statistician Reads JAMA: A Futile Issue 46:13
  19. Response-Adaptive Randomization in Clinical Trials 47:19
  20. REMAP-CAP: The Origin 53:29
  21. Fighting Time in Adaptive Trials 56:09
  22. ICECAP: The Adaptive Design 51:23
  23. Multi-Platform RCT 32:40
  24. Sports and Clinical Trials: The 1927 Yankees, 15 Tarzans, and Modern Athletes 51:16
  25. AI @ Berry 51:06
  26. Drug Development and Sports: The 10-Run Rule and Futility 51:59
  27. ICH-E20, Regulators, and False Choices 41:02
  28. PANTHER: A Phase 2 International Platform Trial in ARDS 52:42
  29. A Visit with Byron Gajewski: KUMC, Innovative Trial Designs, the HOBIT Trial 40:23
  30. A Visit with Stephen Senn: Time, Concurrent Controls, and the Bayesian Guidance 47:24
  31. Making Sense of Hierarchical Composites 53:32
  32. The SNAP Trial with Professors Tong and Davis 53:53
  33. Bayesian Borrowing in Phase 3 Trials 46:38
  34. The Art of Storytelling with Shaun Cassidy 52:22
  35. The Fallacy of Ordinal Endpoints 43:54
  36. Mr. Berry Goes to Washington 47:14
  37. Platform Trial in Orthopaedic Surgery 40:56
  38. A Visit with Michael Harhay 39:08
  39. The FDA Bayesian Guidance 43:20
  40. Path 2 Parkinson's Prevention with Drs. Simuni and Wendelberger 41:39
  41. Statistical Communication 41:31
  42. The Rumor of One Trial for Substantial Evidence 40:11
  43. Communication for Scientists: A Discussion with Jenny Devenport 39:37
  44. Navigating the Arena: Platform Trials 50:27
  45. Jumping Hurdles: Interim Analyses for Funding Decisions 42:19
  46. Discussion with Kaspar Rufibach 47:18
  47. Bayesian Statistics in Clinical trials: The Past, Present, and Future 1:07:17
  48. A Visit with Stroke Neurologist Dr. Jeff Saver 36:59
  49. The Saga of the Lecanemab Adaptive Phase II Trial 51:46
  50. Teaching Statistics and Data Science through Sports with Dr. Jim Albert 38:11